Visit the ACCC COVID-19 Resource Center & Listserv for Insights on Providing Optimal Patient Care During the Pandemic.

ossn-diamonds-nos-left

Providing a VOICE for Nevada's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1993

ossn-diamonds-nos-right

Join/Renew
About
Meetings & Education
- Upcoming Events
Resources
Industry

Industry News Archive

ASCO Announces Virtual Annual Meeting
CMS FAQs on Medicare Provider Enrollment Relief in Response to COVID-19
CMS Announces Exceptions & Extensions for Quality Reporting Requirements
CMS Posts Fact Sheet on Coverage for COVID-19 Tests
Report to the Nation Shows Overall Decline in Cancer Death Rates
Udenyca Well Prepared to Meet Market Demand
FDA Approves Sarclisa® for Relapsed Refractory Multiple Myeloma
CMS Issues Proposed Changes to Medicare Advantage & Part D
FDA Approves Avapritinib for GIST Subset
ACS Report Finds Largest One-Year Drop in Cancer Deaths
FDA Approves Pembrolizumab for Treatment of Subset of Bladder Cancer Patients
FDA Approves Olaparib for Pancreatic Cancer
FDA Approves Enhertu for Previously Treated Unresectable or Metastatic HER2+ Breast Cancer
FDA Approves Padcev (enfortumab vedotin-ejfv) for Advanced Urothelial Cancer
Trump Administration Issues Proposed Rule on Importation of Prescription Drugs
FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer
Senate Confirms Dr. Stephen Hahn as U.S. FDA Commissioner
FDA Approves Atezolizumab + Chemotherapy for Metastatic Non-Squamous NSCLC
FDA Approves New Treatment Option for CLL Under International Collaboration
CMS Issues Rules on Price Transparency for Hospitals and Health Insurance Issuers
FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma
FDA Office of Hematology Oncology Products, Now Called Office of Oncologic Diseases
CMS Issues RFI on Oncology Care First Model
CMS to Hold Nov. 6 Call on PFS and OPPS Final Rules
CMS Releases CY 2020 Final Medicare Payment Rules
FDA Approves Niraparib for HRD-positive Advanced Ovarian Cancer
NAM Issues Report on Systems Approach to Supporting Clinician Well-Being
FDA Approves Daratumumab in Combination for Frontline Multiple Myeloma
With Project Orbis Collaboration, FDA Approves New Treatment for Endometrial Cancer
FDA Approves Fedratinib for Intermediate-2 or High-Risk Myelofibrosis
FDA Grants Acalabrutinib (Calquence) Breakthrough Therapy Designation
CMS Finalizes NCD for CAR T-Cell Therapy
HHS Issues Plan Outlining 2 Paths for Prescription Drug Importation
FDA Approves Pembrolizumab for PD-L1 Positive Advanced SCC of Esophagus
CMS Releases Proposed 2020 OPPS and PFS Rules
FDA Approves Ruxience (rituximab-pvvr) for Adult NHL, CLL, Some Auto-Immune Conditions
ACCC Summary of RO Model Highlights Key Considerations
Administration Withdraws Proposed Drug Rebate Rule
CMS Releases Proposed Radiation Oncology Model Rule
FDA Approves Selinexor for Multiple Myeloma
Information on Keytruda Dosing & Testing Requirements
FDA Approves Pembrolizumab for Metastatic SCLC
FDA Approves Biosimilar Trastuzumab-anns for All Approved Herceptin Indications
FDA Approves First-Line Pembrolizumab for Metastatic or Unresectable HNSCC
FDA Approves Alpelisib for Metastatic Breast Cancer
FDA Approves Ruxolitinib for Acute Graft-Versus-Host Disease
FDA Approves Avelumab Plus Axitinib for Advanced RCC
FDA Approves Pembrolizumab + Axitinib for Advanced Renal Cell Carcinoma
FDA Expands Pembrolizumab Indication to Include First-Line NSCLC Treatment
FDA Expands Palbociclib Use to Include Male Breast Cancer Patients
HCPCS Assigns J-Code and ASP for Imfinzi
FDA Approves Trastuzumab-qyyp as Biosimilar to Herceptin
FDA Approves Pembrolizumab for Melanoma
Medicare Coverage Established for MRD Testing for ALL, Multiple Myeloma
FDA Approves Olaparib for Ovarian, Fallopian, Peritoneal Cancers
FDA Approves Pembrolizumab for Merkel Cell Carcinoma
CMS Assigns Unique HCPCS Code for Imfinzi
FDA Approves Glasdegib for Acute Myeloid Leukemia
Imfinzi Assigned Unique HCPCS Code for Reimbursement by CMS
FDA Approves Pembrolizumab for Hepatocellular Carcinoma
FDA Approves Elotuzumab, Pomalidomide, Dexamethasone for Multiple Myeloma
FDA Approves Lorlatinib for ALK+ Metastatic NSCLC
FDA Approves Pembrolizumab for First-Line Treatment of Metastatic Squamous NSCLC
FDA Approves Talazoparib for gBRCAm HER2- Breast Cancer
FDA Expands Approval of HPV Vaccine to People Aged 27 to 45
Imfinzi Demonstrates Overall Survival Benefit in Stage III Lung Cancer
FDA Approves Dacomitinib for Metastatic NSCLC
FDA Approves New Treatment for Hairy Cell Leukemia
FDA Approves Pembrolizumab + Chemotherapy for NSqNSCLC
FDA Approves Nivolumab for Previously Treated SCLC Patients
FDA Approves Ribociclib in Combination for Advanced, Metastatic Breast Cancer
FDA Approves Nivolumab Plus Ipilimumab for Metastatic Colorectal Cancer
CMS Posts MIPS Final Scores, Performance Feedback for Review
FDA Restricts Use of Keytruda and Tecentriq for Urothelial Cancer
Pfizer’s Biosimilar Retacrit® Receives Q-Codes
FDA Approves Pembrolizumab for Treatment of PMBCL
FDA Approves Pembrolizumab for Advanced Cervical Cancer
Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA
CMS Begins Mailing Out New Medicare Cards
Trump Administration Announces MyHealthEData Initiative

Tweets by OSSatACCC

Contact Us

Get Connected

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
nos-nevada.com
Email Us

Engage & Succeed

Copyright © 2020 Oncology State Societies at ACCC. All rights reserved. Privacy Policy